-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Potential of adult neural stem cells for cellular therapy
(3064) Views (468) Full article downloads
Author: Philippe Taupin
Published Date October 2007
Volume 2007:1(1) Pages 53 - 58
DOI: http://dx.doi.org/10.2147/BTT.S
Philippe Taupin
National Neuroscience Institute, Singapore, Singapore
Abstract: Cellular therapy is the replacement of unhealthy or damaged cells or tissues by new ones. Because neurodegenerative diseases, cerebral strokes, and traumatic injuries to the central nervous system (CNS) produce neurological deficits that result from neuronal loss, cell therapy is a prominent area of investigation for the treatment of neurological diseases and injuries. Neural progenitor and stem cells generate the main phenotyes of the nervous system, and offer a model of choice for cellular therapy in the CNS. With the confirmation that neurogenesis occurs in the adult brain, and the recent isolation and characterization in vitro of neural progenitor and stem cells from the adult CNS, new strategies are being devised and have the potential to treat a broad range of CNS diseases and injuries.
Keywords: neurogenesis, central nervous system, neurodegenerative diseases, trophic factors, regeneration, transplantation
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




